Valneva SE, Chikungunya and Phases of clinical research
Valneva Reports Positive Phase 2 Results in Children for its Chikungunya Vaccine and Announces Phase 3 Dose Decision
Valneva’s vaccine was highly immunogenic in both dose groups. A full dose of the vaccine exhibited a more robust immune response compared to a half dose by providing protective antibody titers already at Day 15 and Day 29 post-vaccination, confirming the excellent immunogenicity previously observed in adults and adolescents 6,7,8,9,10.
Valneva shares positive phase 3 results for chikungunya vaccine in adolescents
Valneva has shared positive results from a late-stage study of its single-dose chikungunya vaccine in adolescents aged 12 to 17 years. The vaccine, Ixchiq, is already approved in the US, Europe and Canada to prevent the mosquito-borne viral disease in individuals aged 18 years and older.
Valneva’s growth potential lies in Ixchiq, but risks remain. Find out why VALN stock is still a Buy with a good long-term ...
Valneva has been awarded funding from the Coalition for Epidemic Preparedness Innovations (CEPI) and EU to expand access to its recently approved vaccine for chikungunya, a potentially life ...
Serum Institute of India CEO Adar Poonawalla spoke to NDTV on a range of issues, key among them the vaccine for malaria and ...
South sensation Samantha Ruth Prabhu recently opened up about her experience with red light therapy as a treatment for joint ...
Indian badminton player HS Prannoy is overcoming challenging setbacks, including health issues, to make a comeback.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback